RxDoctor Payments Data

Kelly Hardesty, NP

Family · Valparaiso, INNPI 1265957971

Payments from drug & device makers

$8,324in general payments, 2019–2025

Across 353 payments — averaging $23.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$2K
  • Paratek Pharmaceuticals, Inc.$2K
  • Gilead$973
  • AbbVie$850
  • Shionogi Inc$699
  • Melinta Therapeutics, LLC$470
  • plus $948 from 11 others

What the payments were for

  • Food & beverage$8,26299%
  • Education$621%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,324 in reported general payments places this provider in the 95th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$65,832
Medicare patients
363
Services billed
852

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuzyraOmadacycline Tosylate37$354,536
Daptomycin47$100,142
ErtapenemErtapenem Sodium16$18,608
Fosfomycin Tromethamine40$11,830
Meropenem27$9,835
Cefepime Hcl15$4,941
CeftriaxoneCeftriaxone Sodium12$2,104
Doxycycline Monohydrate60$1,426
Cephalexin67$789
Doxycycline Hyclate35$540
Cefazolin Sodium26$538
Cefdinir32$513
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav28$329
Fluconazole24$173
Levofloxacin34$152

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Paratek Pharmaceuticals, Inc.Nuzyra$2,166$354,53637 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,392 family providers in Indiana.

Other family in Valparaiso

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →